Exosome Diagnostics, a Bio-Techne brand, is based outside of Boston, MA and is focused on developing and commercializing revolutionary, exosome-based diagnostics to deliver personalized precision healthcare that improves lives.
Our liquid biopsy, ExoDx™ Prostate Intelliscore), or EPI, is a simple urine test that delivers unique, actionable intelligence to help with the prostate biopsy decision. The EPI score is not influenced by standard of care or common clinical features such as DRE, family history, or PSA level. Recent clinical studies have shown that The EPI Test improves patient compliance and identifies more high- grade prostate cancers (HGPCa) compared to standard of care alone.
The ExoDx Prostate Test is included in the May 2019 National Comprehensive Cancer Network guidelines (NCCN guidelines) for early detection of prostate cancer, received FDA Breakthrough Device designation, is covered by Medicare, and available in all 50 states. ExosomeDx.com.
Brands: ExoDx Prostate(IntelliScore) or EPI